Mechanism of Drug-Drug Interactions Between Warfarin and Statins.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmacy and Science

• Publication date

  2016-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.xphs.2016.03.011PMID 27103011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry.

  2016cited by this paper
• Dealing with the complex drug-drug interactions: towards mechanistic models.

  2015cited by this paper
• ROLE OF PLASMA PROTEIN BINDING DISPLACEMENT IN DRUG-DRUG INTERACTIONS BETWEEN WARFARIN AND STATINS

  2014cited by this paper
• The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

  2013cited by this paper
• Evaluation and Prediction of Potential Drug-Drug Interactions of Linagliptin Using In Vitro Cell Culture Methods

  2013cited by this paper
• Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1

  2013cited by this paper
• Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin.

  2012cited by this paper
• Emergency hospitalizations for adverse drug events in older Americans.

  2011cited by this paper
• Effect of Single‐Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers

  2010cited by this paper
• Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

  2010cited by this paper
• Warfarin: history, tautomerism and activity

  2010cited by this paper
• The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

  2010cited by this paper
• Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.

  2010cited by this paper
• The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations

  2009cited by this paper
• Prevalence and predictors of potential drug–drug interactions in Regione Emilia‐Romagna, Italy

  2008cited by this paper
• Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.

  2007cited by this paper
• Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

  2007cited by this paper
• Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolam—Probes of CYP2C9, CYP1A2, and CYP3A4

  2007cited by this paper
• Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.

  2007cited by this paper
• Probable Warfarin–Simvastatin Interaction

  2007cited by this paper
• Warfarin: almost 60 years old and still causing problems.

  2006cited by this paper
• Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

  2006cited by this paper
• Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes

  2006cited by this paper
• Atypical Cytochrome P450 Kinetics

  2006cited by this paper
• Warfarin and its interactions with foods, herbs and other dietary supplements

  2006cited by this paper
• Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• Rosuvastatin-acenocoumarol interaction.

  2005cited by this paper
• Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

  2005cited by this paper
• Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.

  2005cited by this paper
• Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature

  2004cited by this paper
• Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

  2004cited by this paper
• Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

  2003cited by this paper
• Clinical pharmacokinetics of statins.

  2003cited by this paper
• Preclinical pharmacokinetics of statins.

  2002cited by this paper
• Determination of transport in the Caco-2 cell assay of compounds varying in lipophilicity using LC-MS: enhanced transport of Leu-enkephalin analogues.

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

  2001cited by this paper
• Rational use of in vitro P-glycoprotein assays in drug discovery.

  2001cited by this paper
• State-of-the-Art Review: The Oral Anticoagulant Saga: Past, Present, and Future

  2001cited by this paper
• HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.

  2000cited by this paper
• Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.

  2000cited by this paper
• Clinical Pharmacokinetics of Cerivastatin

  2000cited by this paper
• Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

  1999cited by this paper
• Human P450 metabolism of warfarin.

  1997cited by this paper
• Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors

  1997cited by this paper
• Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.

  1997cited by this paper
• Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

  1996cited by this paper
• Multiple‐dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG‐CoA reductase, in healthy subjects

  1996cited by this paper
• Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.

  1996cited by this paper
• Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

  1996cited by this paper
• In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

  1996cited by this paper
• Lovastatin during warfarin therapy resulting in bleeding.

  1995cited by this paper
• Lovastatin during warfarin therapy resulting in bleeding.

  1995cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

  1993cited by this paper
• Pharmacokinetics of Pravastatin in Elderly versus Young Men and Women

  1993cited by this paper
• Methods of Determining Plasma and Tissue Binding of Drugs

  1992cited by this paper
• A receptor-mediated pathway for cholesterol homeostasis.

  1986cited by this paper
• Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.

  1984cited by this paper
• Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.

  1983cited by this paper

• The Application of Machine Learning in Warfarin Dose Precision for Diabetic Patients Treated with Statins: A Comparative Study.

  2025cites this paper
• Pharmaceuticals and Microplastics in Aquatic Environments: A Comprehensive Review of Pathways and Distribution, Toxicological and Ecological Effects

  2025cites this paper
• Optimizing warfarin dosing in diabetic patients through BERT model and machine learning techniques

  2025cites this paper
• Role of carbon nanotubes in remediation of pharmaceutical wastewater

  2024cites this paper
• The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS)

  2023cites this paper
• Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants

  2022cites this paper
• Management of patients with statin intolerance.

  2022cites this paper
• Drug Interactions Affecting Oral Anticoagulant Use

  2022cites this paper
• Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)

  2022cites this paper
• Commonly Prescribed Medications that Affect Clotting: A Comprehensive Overview

  2021cites this paper
• Potential Cardiovascular Drug Interactions in Egypt: Incidence, Outcomes, Mechanism, and Management

  2021cites this paper
• Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies

  2021cites this paper
• Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

  2021cites this paper
• Evaluation of the combination of Kemuning Leaves Extracts and Simvastatin on Blood fatty acids and amino acids of Hyperlipidemic Model Rats

  2021cites this paper
• An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data set

  2021cites this paper
• The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis

  2020cites this paper
• Statins and muscle pain

  2020cites this paper
• Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors

  2020cites this paper
• Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3).

  2020cites this paper
• Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors

  2020cites this paper
• Influence of Flavonoids from Galium verum L. on the activities of cytochrome P450 isozymes and pharmacokinetic and pharmacodynamic of warfarin in rats

  2019cites this paper
• Design flaws in statins and pancreatic cancer research

  2019cites this paper
• Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.

  2019cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development

  2019cites this paper
• Improving Prediction of Systemic Statin Exposure Using Concomitant Medications, Non-Linear Modelling and Novel SNP Discovery

  2018cites this paper
• Food–drug interactions involving multiple mechanisms: A case study with effect of Capsaicin on the pharmacokinetics of Irinotecan and its main metabolites in rat

  2018cites this paper
• Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes Over Long Timeframes

  2018cites this paper
• Statins do not Increase the Rate of Bleeding Among Warfarin Users

  2018cites this paper
• Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Health risks associated with the pharmaceuticals in wastewater

  2017cites this paper
• Interaction of antihypertensive drugs and rosuvastatin: focus on safety, efficiency and prospects

  2017cites this paper
• Statins: All you need to know

  2017cites this paper
• Warfarin-chlorophyll products, herb-drug interactions

  2017cites this paper
• A Race‐Specific Interaction Between Vitamin K Status and Statin Use During Warfarin Therapy Initiation

  2017cites this paper
• Drug-Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4.

  2017cites this paper
• Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.

  2017cites this paper
• Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation

  2017cites this paper
• Quantification of Warfarin in Dried Rat Plasma Spots by High-Performance Liquid Chromatography with Tandem Mass Spectrometry

  2016cites this paper
• Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent

  2016cites this paper